Despite Key Patent Losses Roche Could Add $5 Billion In Sales Over The Next 3 Years
- Wednesday, October 30, 2019, 7:10
- Market
- Add a comment
Roche Holding (SWX: ROG) has added roughly $6 billion in sales between 2015-2018. However, the company’s key blockbuster drugs – Avastin, Herceptin, and Rituxan – will likely be competing with biosimilars given the patent losses. In fact, we calculate $3 billion in expected lost sales…
About the Author
admin123 has written 23409 stories on this site.
